

Yoon-La Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1670167/publications.pdf>

Version: 2024-02-01

183
papers

6,105
citations

61984

43
h-index

102487

66
g-index

183
all docs

183
docs citations

183
times ranked

10247
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing-Based NTRK Fusion Detection in South Korea. <i>Cancer Research and Treatment</i> , 2023, 55, 28-40. | 3.0 | 4 |
| 2 | Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer. <i>Cancer Research and Treatment</i> , 2023, 55, 145-154. | 3.0 | 2 |
| 3 | Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 751-762. | 6.4 | 5 |
| 4 | Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma. <i>Cancer Research and Treatment</i> , 2022, 54, 782-792. | 3.0 | 3 |
| 5 | Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2-CCR2 signaling. <i>Laboratory Investigation</i> , 2022, 102, 376-390. | 3.7 | 24 |
| 6 | Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2321-2328. | 7.0 | 7 |
| 7 | Abstract PD2-08: Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib. <i>Cancer Research</i> , 2022, 82, PD2-08-PD2-08. | 0.9 | 1 |
| 8 | Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. <i>Cancer</i> , 2022, 128, 2148-2158. | 4.1 | 19 |
| 9 | Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928. | 1.6 | 94 |
| 10 | Prognostic impact of micropapillary and solid histological subtype on patients undergoing curative resection for stage I lung adenocarcinoma according to the extent of pulmonary resection and lymph node assessment. <i>Lung Cancer</i> , 2022, 168, 21-29. | 2.0 | 5 |
| 11 | Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.. <i>American Journal of Cancer Research</i> , 2022, 12, 1393-1408. | 1.4 | 0 |
| 12 | Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 169, 42-53. | 2.8 | 10 |
| 13 | Artificial intelligence-powered programmed death ligand-1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response. <i>European Journal of Cancer</i> , 2022, 170, 17-26. | 2.8 | 21 |
| 14 | The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across 16 primary tumor types.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2621-2621. | 1.6 | 1 |
| 15 | Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1271. | 7.1 | 15 |
| 16 | Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4312-4321. | 7.0 | 7 |
| 17 | Second primary pleomorphic carcinoma arising from the pneumonectomy cavity of non-small cell lung cancer: A case report. <i>Respiratory Medicine Case Reports</i> , 2021, 32, 101373. | 0.4 | 0 |
| 18 | TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis. <i>Cancer Research and Treatment</i> , 2021, 53, 9-24. | 3.0 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | High concordance of actionable genomic alterations identified between circulating tumor DNAâ€‘based and tissueâ€‘based nextâ€‘generation sequencing testing in advanced nonâ€‘small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028. | 4.1 | 37 |
| 20 | Mitochondrial DNA Copy Number Assist with Diagnosis of Vague Myopathy. <i>FASEB Journal</i> , 2021, 35, . | 0.5 | 0 |
| 21 | Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by an artificial intelligence-powered tissue analyzer in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21012-e21012. | 1.6 | 0 |
| 22 | Molecular biomarker testing for nonâ€‘small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 181-191. | 1.1 | 10 |
| 23 | Overexpression of Replication-Dependent Histone Signifies a Subset of Dedifferentiated Liposarcoma with Increased Aggressiveness. <i>Cancers</i> , 2021, 13, 3122. | 3.7 | 7 |
| 24 | Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2021, 11, 1695. | 2.6 | 3 |
| 25 | PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. <i>Cancers</i> , 2021, 13, 4659. | 3.7 | 20 |
| 26 | Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4671-4692. | 2.0 | 6 |
| 27 | <scp><i>NTRK</i></scp> oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions. <i>Journal of Pathology</i> , 2021, 255, 399-411. | 4.5 | 8 |
| 28 | Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 4209-4220. | 2.8 | 6 |
| 29 | Lung Cancer in Korea. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1988-1993. | 1.1 | 5 |
| 30 | Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1009-1015. | 2.8 | 27 |
| 31 | Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index. <i>European Radiology</i> , 2020, 30, 914-924. | 4.5 | 42 |
| 32 | Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting. <i>Biomolecules</i> , 2020, 10, 51. | 4.0 | 7 |
| 33 | Junction Location Identifier (JuLI). <i>Journal of Molecular Diagnostics</i> , 2020, 22, 304-318. | 2.8 | 6 |
| 34 | Benefit of Targeted DNA Sequencing in Advanced Nonâ€‘Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020, 21, e182-e190. | 2.6 | 5 |
| 35 | Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199. | | 7 |
| 36 | Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A singleâ€‘institute experience of 10 cases. <i>Thoracic Cancer</i> , 2020, 11, 3205-3212. | 1.9 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma. <i>IScience</i> , 2020, 23, 101386. | 4.1 | 5 |
| 38 | Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2020, 12, 5357-5368. | 1.4 | 8 |
| 39 | Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. <i>Nature Communications</i> , 2020, 11, 6175. | 12.8 | 92 |
| 40 | Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020, 11, 2285. | 12.8 | 565 |
| 41 | Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. <i>Cancers</i> , 2020, 12, 1575. | 3.7 | 8 |
| 42 | An Immuneâ€Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood. <i>Micromachines</i> , 2020, 11, 560. | 2.9 | 12 |
| 43 | Dysregulation of cancer genes by recurrent intergenic fusions. <i>Genome Biology</i> , 2020, 21, 166. | 8.8 | 22 |
| 44 | UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 9, 1574. | 2.8 | 27 |
| 45 | IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 188-196. | 4.4 | 6 |
| 46 | Current status and future perspectives of liquid biopsy in non-small cell lung cancer. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 204-212. | 1.1 | 17 |
| 47 | Molecular changes in solitary fibrous tumor progression. <i>Journal of Molecular Medicine</i> , 2019, 97, 1413-1425. | 3.9 | 47 |
| 48 | Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 667. | 2.8 | 12 |
| 49 | Adipogenesis induces growth inhibition of dedifferentiated liposarcoma. <i>Cancer Science</i> , 2019, 110, 2676-2683. | 3.9 | 14 |
| 50 | Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74. | 2.8 | 33 |
| 51 | Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4794. | 4.1 | 29 |
| 52 | Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. <i>Clinical Lung Cancer</i> , 2019, 20, e309-e316. | 2.6 | 11 |
| 53 | Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 193-202. | 1.1 | 104 |
| 54 | Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology. <i>Laboratory Investigation</i> , 2019, 99, 1309-1320. | 3.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Capsule biopsy of acellular dermal matrix (ADM) to predict future capsular contracture in two-stage prosthetic breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1576-1606. | 1.0 | 6 |
| 56 | Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers. <i>Pathology Research and Practice</i> , 2019, 215, 152441. | 2.3 | 12 |
| 57 | Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma. <i>Molecular Oncology</i> , 2019, 13, 1356-1368. | 4.6 | 39 |
| 58 | Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019, 130, 87-92. | 2.0 | 39 |
| 59 | Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 347-353. | 1.1 | 24 |
| 60 | High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy. <i>Breast Cancer Research</i> , 2019, 21, 127. | 5.0 | 16 |
| 61 | High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 20197. | 3.3 | 15 |
| 62 | EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501. | 3.0 | 30 |
| 63 | Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 623-631. | 3.0 | 40 |
| 64 | Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 335-345. | 3.4 | 19 |
| 65 | Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA. <i>Scientific Reports</i> , 2018, 8, 543. | 3.3 | 16 |
| 66 | Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. <i>Nature Communications</i> , 2018, 9, 1725. | 12.8 | 122 |
| 67 | Clinical benefit and residual kidney function of en bloc nephrectomy for perirenal retroperitoneal sarcoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e465-e471. | 1.1 | 4 |
| 68 | Radical Nephrectomy for Primary Retroperitoneal Liposarcoma Near the Kidney has a Beneficial Effect on Disease-Free Survival. <i>World Journal of Surgery</i> , 2018, 42, 254-262. | 1.6 | 9 |
| 69 | Status of programmed death-ligand 1 expression in sarcomas. <i>Journal of Translational Medicine</i> , 2018, 16, 303. | 4.4 | 33 |
| 70 | Integrin $\beta 3$ Inhibition Enhances the Antitumor Activity of ALK Inhibitor in <i>ALK</i> -Rearranged NSCLC. <i>Clinical Cancer Research</i> , 2018, 24, 4162-4174. | 7.0 | 13 |
| 71 | Genomic alterations of ground-glass nodular lung adenocarcinoma. <i>Scientific Reports</i> , 2018, 8, 7691. | 3.3 | 10 |
| 72 | Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164. | 2.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Sigmoid colon perforation after postoperative hypofractionated intensity-modulated radiation therapy in a cervical cancer patient. <i>Cancer Reports</i> , 2018, 1, e1129. | 1.4 | 1 |
| 74 | Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors. <i>Journal of Korean Medical Science</i> , 2018, 33, e123. | 2.5 | 5 |
| 75 | Abrupt Dyskeratotic and Squamoid Cells in Poorly Differentiated Carcinoma: Case Study of Two Thoracic NUT Midline Carcinomas with Cytohistologic Correlation. <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 349-353. | 1.1 | 12 |
| 76 | Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 95-102. | 3.0 | 22 |
| 77 | Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21136-e21136. | 1.6 | 0 |
| 78 | Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. <i>World Journal of Surgery</i> , 2017, 41, 1820-1827. | 1.6 | 33 |
| 79 | Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. <i>Gut</i> , 2017, 66, 215-225. | 12.1 | 34 |
| 80 | Genomic profiling of esophageal squamous cell carcinoma (ESCC)â€”Basis for precision medicine. <i>Pathology Research and Practice</i> , 2017, 213, 836-841. | 2.3 | 16 |
| 81 | A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2âˆ’ early breast cancer. <i>Scientific Reports</i> , 2017, 7, 45554. | 3.3 | 26 |
| 82 | MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 41-56. | 2.5 | 51 |
| 83 | MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1233-1246. | 1.1 | 68 |
| 84 | Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq. <i>Lung Cancer</i> , 2017, 109, 21-27. | 2.0 | 26 |
| 85 | Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of <i>BRAF</i> ^{V600E} Mutation. <i>Thyroid</i> , 2017, 27, 802-810. | 4.5 | 78 |
| 86 | Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer. <i>Pathology</i> , 2017, 49, 618-626. | 0.6 | 14 |
| 87 | Therapeutic strategies for locally recurrent and metastatic de-differentiated liposarcoma with herpes simplex virusâ€”thymidine kinaseâ€”expressing mesenchymal stromal cells. <i>Cytotherapy</i> , 2017, 19, 1035-1047. | 0.7 | 6 |
| 88 | Programmed Death Ligand 1 Expression in Paired Nonâ€”Small Cell Lung Cancer Tumor Samples. <i>Clinical Lung Cancer</i> , 2017, 18, e473-e479. | 2.6 | 35 |
| 89 | Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation of TP53/E2F Dynamic Behavior for Cell Fate Decisions. <i>Neoplasia</i> , 2017, 19, 735-749. | 5.3 | 14 |
| 90 | Diagnostic Limitation of Fine-Needle Aspiration (FNA) on Indeterminate Thyroid Nodules Can Be Partially Overcome by Preoperative Molecular Analysis: Assessment of RET/PTC1 Rearrangement in BRAF and RAS Wild-Type Routine Air-Dried FNA Specimens. <i>International Journal of Molecular Sciences</i> , 2017, 18, 806. | 4.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification. BMC Cancer, 2017, 17, 535. | 2.6 | 3 |
| 92 | Molecular Testing of Lung Cancers. Journal of Pathology and Translational Medicine, 2017, 51, 242-254. | 1.1 | 26 |
| 93 | Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests. Journal of Pathology and Translational Medicine, 2017, 51, 191-204. | 1.1 | 42 |
| 94 | Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. Oncotarget, 2017, 8, 61538-61550. | 1.8 | 28 |
| 95 | Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (<i>ALK</i>)-rearranged non-small cell lung cancer. Journal of Pathology, 2017, 243, 307-319. | 4.5 | 63 |
| 96 | Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans. PLoS ONE, 2017, 12, e0185826. | 2.5 | 10 |
| 97 | Comparison of retroperitoneal liposarcoma extending into the inguinal canal and inguinoscrotal liposarcoma. Canadian Journal of Surgery, 2017, 60, 399-407. | 1.2 | 9 |
| 98 | <i>KRAS</i> mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 3519-3527. | 1.8 | 11 |
| 99 | Genes co-amplified with <i>ERBB2</i> or <i>MET</i> as novel potential cancer-promoting genes in gastric cancer. Oncotarget, 2017, 8, 92209-92226. | 1.8 | 26 |
| 100 | Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Journal of Pathology and Translational Medicine, 2017, 51, 441-443. | 1.1 | 9 |
| 101 | Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. Cancer Research and Treatment, 2017, 49, 915-926. | 3.0 | 58 |
| 102 | Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients. Cancer Research and Treatment, 2017, 49, 1065-1076. | 3.0 | 11 |
| 103 | Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma. Oncotarget, 2016, 7, 67302-67313. | 1.8 | 76 |
| 104 | The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Journal of Thoracic Disease, 2016, 8, 3175-3186. | 1.4 | 4 |
| 105 | Efficacy and safety of dolutinib in pretreated patients with advanced squamous non-small cell lung cancer with <i>FGFR1</i> amplification: A single-arm, phase 2 study. Cancer, 2016, 122, 3024-3031. | 4.1 | 72 |
| 106 | Prognostic Significance of <i>TERT</i> Promoter Mutations in Papillary Thyroid Carcinomas in a <i>BRAF</i> ^{V600E} Mutation-Prevalent Population. Thyroid, 2016, 26, 901-910. | 4.5 | 69 |
| 107 | Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing. American Journal of Human Genetics, 2016, 98, 843-856. | 6.2 | 33 |
| 108 | Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 2129-2140. | 1.1 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1003-1011. | 1.1 | 130 |
| 110 | Efficiency of methylated DNA immunoprecipitation bisulphite sequencing for whole-genome DNA methylation analysis. <i>Epigenomics</i> , 2016, 8, 1061-1077. | 2.1 | 11 |
| 111 | Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, e1-e4. | 1.1 | 76 |
| 112 | Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e45-e47. | 1.1 | 98 |
| 113 | Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion. <i>Journal of Clinical Pathology</i> , 2016, 69, 586-592. | 2.0 | 13 |
| 114 | ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. <i>Lung Cancer</i> , 2016, 94, 22-27. | 2.0 | 56 |
| 115 | Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 283-312. | 22.4 | 106 |
| 116 | A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. <i>Journal of Clinical Oncology</i> , 2016, 34, 9013-9013. | 1.6 | 16 |
| 117 | Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. <i>Oncotarget</i> , 2016, 7, 62676-62686. | 1.8 | 6 |
| 118 | LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients. <i>Oncotarget</i> , 2016, 7, 82876-82888. | 1.8 | 11 |
| 119 | Integrated genomic approaches identify upregulation of <i>SCRN1</i> as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. <i>Oncotarget</i> , 2016, 7, 13797-13809. | 1.8 | 7 |
| 120 | Clinicopathologic characteristics of <i>EGFR</i> , <i>KRAS</i> , and <i>ALK</i> alterations in 6,595 lung cancers. <i>Oncotarget</i> , 2016, 7, 23874-23884. | 1.8 | 62 |
| 121 | <i>PIK3CA</i> amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 30691-30701. | 1.8 | 28 |
| 122 | Identification of a novel partner gene, <i>KIAA1217</i> , fused to <i>RET</i> : Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 36101-36114. | 1.8 | 31 |
| 123 | Non-small Cell Lung Cancer with Concomitant <i>EGFR</i> , <i>KRAS</i> , and <i>ALK</i> Mutation: Clinicopathologic Features of 12 Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 197-203. | 1.1 | 73 |
| 124 | Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 258-263. | 1.1 | 50 |
| 125 | <i>SEC31A-ALK</i> Fusion Gene in Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 398-402. | 3.0 | 27 |
| 126 | A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 514-523. | 1.9 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Cytomorphological identification of advanced pulmonary adenocarcinoma harboring <sc>KRAS</sc> mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with <sc>KRAS</sc> and <sc>EGFR</sc> mutations. Diagnostic Cytopathology, 2015, 43, 539-544. | 1.0 | 5 |
| 128 | Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. International Journal of Molecular Sciences, 2015, 16, 12243-12260. | 4.1 | 19 |
| 129 | CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer. PLoS ONE, 2015, 10, e0139112. | 2.5 | 78 |
| 130 | Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples. PLoS ONE, 2015, 10, e0144162. | 2.5 | 76 |
| 131 | Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving <i>EGFR</i>. Oncotarget, 2015, 6, 5465-5474. | 1.8 | 116 |
| 132 | Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9722-9727. | 7.1 | 53 |
| 133 | Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With-epidermal Growth Factor Receptor Mutant- Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor- Therapy. Clinical Lung Cancer, 2015, 16, 228-236. | 2.6 | 23 |
| 134 | Patient-Derived Xenografts from Non- Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy. Clinical Cancer Research, 2015, 21, 1172-1182. | 7.0 | 58 |
| 135 | Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non- Small-Cell Lung Cancer: KCSG-LU05-04. Journal of Clinical Oncology, 2015, 33, 2660-2666. | 1.6 | 215 |
| 136 | Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Modern Pathology, 2015, 28, 468-479. | 5.5 | 114 |
| 137 | Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 2562-2572. | 1.8 | 30 |
| 138 | Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. Oncotarget, 2015, 6, 32027-32038. | 1.8 | 36 |
| 139 | HER2 as a novel therapeutic target for cervical cancer. Oncotarget, 2015, 6, 36219-36230. | 1.8 | 51 |
| 140 | Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma. Journal of Pathology and Translational Medicine, 2015, 49, 310-317. | 1.1 | 22 |
| 141 | Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines. PLoS ONE, 2014, 9, e88587. | 2.5 | 25 |
| 142 | Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?. PLoS ONE, 2014, 9, e88598. | 2.5 | 47 |
| 143 | Polyostotic Fibrous Dysplasia Mimicking Multiple Bone Metastases in a Patient with Ductal Carcinoma In Situ. Journal of Breast Cancer, 2014, 17, 83. | 1.9 | 5 |
| 144 | Synchronous Triple Primary Lung Cancers: A Case Report. Korean Journal of Radiology, 2014, 15, 646. | 3.4 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2527-2536. | 4.1 | 34 |
| 146 | SMAD4 Suppresses AURKA-Induced Metastatic Phenotypes via Degradation of AURKA in a TGF β 2-Independent Manner. <i>Molecular Cancer Research</i> , 2014, 12, 1779-1795. | 3.4 | 20 |
| 147 | <i>KRAS</i> Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing. <i>Korean Journal of Pathology</i> , 2014, 48, 100. | 1.3 | 20 |
| 148 | Extrapulmonary Lymphangioliomyoma: Clinicopathological Analysis of 4 Cases. <i>Korean Journal of Pathology</i> , 2014, 48, 188. | 1.3 | 11 |
| 149 | Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014, 83, 259-264. | 2.0 | 30 |
| 150 | A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 229-243. | 2.8 | 105 |
| 151 | FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e23-49.e31. | 1.6 | 34 |
| 152 | The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex. <i>Experimental and Molecular Pathology</i> , 2014, 97, 440-444. | 2.1 | 5 |
| 153 | Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. <i>Genomics</i> , 2014, 104, 234-241. | 2.9 | 58 |
| 154 | Pleural epithelioid hemangioendothelioma harboring CAMTA1 rearrangement. <i>Lung Cancer</i> , 2014, 83, 411-415. | 2.0 | 21 |
| 155 | Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors. <i>Journal of Surgical Research</i> , 2014, 187, 502-509. | 1.6 | 41 |
| 156 | A Novel Fusion of TPR and ALK in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 563-566. | 1.1 | 83 |
| 157 | Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling. <i>Scientific Reports</i> , 2014, 4, 3623. | 3.3 | 25 |
| 158 | PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea. <i>Journal of Clinical Oncology</i> , 2014, 32, 8066-8066. | 1.6 | 9 |
| 159 | CDK4 Amplification Predicts Recurrence of Well-Differentiated Liposarcoma of the Abdomen. <i>PLoS ONE</i> , 2014, 9, e99452. | 2.5 | 17 |
| 160 | Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. <i>Oncotarget</i> , 2014, 5, 9065-9078. | 1.8 | 16 |
| 161 | The presence of ALK translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series. <i>Journal of Clinical Oncology</i> , 2014, 32, e17048-e17048. | 1.6 | 0 |
| 162 | A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations. <i>Journal of Clinical Oncology</i> , 2014, 32, e19155-e19155. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. <i>Histology and Histopathology</i> , 2014, 29, 127-38. | 0.7 | 30 |
| 164 | <scp>EGFR</scp> and <scp>KRAS</scp> mutation analyses from specimens obtained by bronchoscopy and <scp>EBUS–TBNA</scp>. <i>Thoracic Cancer</i> , 2013, 4, 264-272. | 1.9 | 8 |
| 165 | EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital. <i>PLoS ONE</i> , 2013, 8, e56011. | 2.5 | 65 |
| 166 | Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2013, 31, 637-637. | 1.6 | 0 |
| 167 | A Dramatic Response to Crizotinib in a Non“Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e36-e38. | 1.1 | 87 |
| 168 | Mucoepidermoid Carcinoma of Tracheobronchial Tree: Clinicopathological Study of 31 Cases. <i>Korean Journal of Pathology</i> , 2011, 45, 175. | 1.3 | 9 |
| 169 | Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. <i>BMC Cancer</i> , 2010, 10, 507. | 2.6 | 46 |
| 170 | One-step Nucleic Acid Amplification (OSNA): Intraoperative Rapid Molecular Diagnostic Method for the Detection of Sentinel Lymph Node Metastases in Breast Cancer Patients in Korean Cohort. <i>Journal of Breast Cancer</i> , 2010, 13, 366. | 1.9 | 3 |
| 171 | LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer. <i>Cancer Research</i> , 2010, 70, 2296-2306. | 0.9 | 128 |
| 172 | Detection of Human Papillomavirus DNA by DNA Chip in Breast Carcinomas of Korean Women. <i>Tumor Biology</i> , 2007, 28, 327-332. | 1.8 | 46 |
| 173 | Overexpression of CD24: Association With Invasiveness in Urothelial Carcinoma of the Bladder. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 275-281. | 2.5 | 26 |
| 174 | Gastric Syphilis Mimicking Adenocarcinoma: A Case Report. <i>Journal of Korean Medical Science</i> , 2006, 21, 559. | 2.5 | 11 |
| 175 | Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 331-336. | 2.8 | 41 |
| 176 | Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. <i>Gynecologic Oncology</i> , 2005, 97, 379-386. | 1.4 | 59 |
| 177 | HULip, a human homologue of unc-33-like phosphoprotein of <i>Caenorhabditis elegans</i> ; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. <i>Journal of Neuro-Oncology</i> , 2005, 73, 19-27. | 2.9 | 7 |
| 178 | Immunoexpression of HBME-1, High Molecular Weight Cytokeratin, Cytokeratin 19, Thyroid Transcription Factor-1, and E-cadherin in Thyroid Carcinomas. <i>Journal of Korean Medical Science</i> , 2005, 20, 853. | 2.5 | 49 |
| 179 | An Immunohistochemical Study of the Expression of Adhesion Molecules in Gallbladder Lesions. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 591-601. | 2.5 | 46 |
| 180 | Cortical laminar disorganization is correlated with severity of the cortical dysplasia and surgical outcome“experience with 150 cases. <i>Epilepsy Research</i> , 2004, 62, 171-178. | 1.6 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Comparative study of non-functional islet cell tumors and pancreatic solid and papillary neoplasms: Biological behavior and immunohistochemistry. Pathology International, 2002, 52, 358-366. | 1.3 | 11 |
| 182 | Cytologic clue of so-called nodular histiocytic hyperplasia of the pleura. Diagnostic Cytopathology, 2001, 24, 256-259. | 1.0 | 17 |
| 183 | Immunoexpression of Inhibin β Subunit, Inhibin/Activin β Subunit and CD99 in Ovarian Tumors. Archives of Pathology and Laboratory Medicine, 2000, 124, 563-569. | 2.5 | 69 |